FDA to GSK: No go on Avodart for prostate cancer
The Food and Drug Administration has denied GlaxoSmithKline's application to add prostate cancer reduction to the indications for Avodart, a drug used to treat an enlarged prostate.
‘No’ vote on broader labels for prostate drugs (Morning Read)
Would the Food and Drug Administration advisory committee recommend that the labels of two drugs -- dutasteride, made by GlaxoSmithKline and sold as Avodart; and finasteride, a generic made by Merck and sold as Proscar -- be changed to say they can reduce a man's risk of getting prostate cancer? The answer was no, reports the New York Times.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.